|
SLEDAI-2 k (points); median (range)
|
12 (6 to 20)
|
14 (2 to 30)
|
|
gender female number (%)
|
15 (65.2)
|
16 (66.7)
|
|
age (years); mean ± SD
|
35 ± 10
|
34 ± 10
|
|
duration (years); median (range)
|
4 (1 to 24)
|
3 (0 to 25)
|
|
age at initial diagnosis of SLE (years); mean ± SD
|
29 ± 10
|
30 ± 10
|
|
medication
| | |
|
prednisone (mg/day); median (range)
|
10.0 (5.0-30.0)
|
10.0 (0.0-250.0)
|
|
co-medication with antimalarials number (%)
|
15 (65.2)
|
11 (45.8)
|
|
preceding immunosuppressive medication number (%)
| | |
|
- CYC
|
11 (47.8)
| |
|
- MMF
| |
6 (25.0)
|
|
- AZA
|
8 (24.8)
|
7 (29.2)
|
|
- MTX
|
2 (8.7)
|
2 (8.3)
|
|
- CsA
|
1 (4.3)
|
1 (4.2)
|
|
- none
|
1 (4.3)a
|
8 (33.3)a
|
|
manifestations number (%)
| |
|
class III-V nephritis flare
|
17 (73.9)
|
18 (75.0)
|
|
eGFR <60 ml/min
|
4 (18.2)
|
6 (25.0)
|
|
C3c <0.9 g/L
|
14 (60.9)b
|
23 (95.8)b
|
|
neuropsychiatric
|
1 (4.3)
|
3 (12.5)
|
|
mucocutaneous/cutaneous
|
14 (60.9)
|
14 (58.3)
|
|
arthritis
|
8 (34.8)
|
6 (25.0)
|
|
serositis
|
2 (8.7)
|
5 (20.8)
|
|
myositis
|
2 (8.7)
|
3 (12.5)
|
|
autoantibodies number (%)
| |
|
anti-dsDNA >7 U/ml
|
21 (91.3)
|
21 (87.5)
|
|
anti-Ro >7 U/ml
|
15 (65.2)
|
13 (54.2)
|
|
anti-La >7 U/ml
|
5 (21.7)
|
5 (20.8)
|
|
anti-U1-RNP >5 U/ml
|
11 (47.8)
|
13 (54.2)
|
|
anti-SM >5 U/ml
|
8 (34.8)
|
11 (45.8)
|
